Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UT-15C sustained-release tablets versus placebo in pulmonary arterial hypertension
2006-000801-50Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing UT-15C SR with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance from baseline to Week 12. Started Jan 2007; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2006-000801-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000801-50.